Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation

PLoS One. 2012;7(5):e37108. doi: 10.1371/journal.pone.0037108. Epub 2012 May 31.

Abstract

To what extent might the regulation of translation contribute to differentiation programs, or to the molecular pathogenesis of cancer? Pre-B cells transformed with the viral oncogene v-Abl are suspended in an immortalized, cycling state that mimics leukemias with a BCR-ABL1 translocation, such as Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Inhibition of the oncogenic Abl kinase with imatinib reverses transformation, allowing progression to the next stage of B cell development. We employed a genome-wide polysome profiling assay called Gradient Encoding to investigate the extent and potential contribution of translational regulation to transformation and differentiation in v-Abl-transformed pre-B cells. Over half of the significantly translationally regulated genes did not change significantly at the level of mRNA abundance, revealing biology that might have been missed by measuring changes in transcript abundance alone. We found extensive, gene-specific changes in translation affecting genes with known roles in B cell signaling and differentiation, cancerous transformation, and cytoskeletal reorganization potentially affecting adhesion. These results highlight a major role for gene-specific translational regulation in remodeling the gene expression program in differentiation and malignant transformation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism*
  • B-Lymphocytes / pathology*
  • Benzamides
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics*
  • Cell Line
  • Cell Transformation, Viral / drug effects
  • Cell Transformation, Viral / genetics*
  • Humans
  • Imatinib Mesylate
  • Oligonucleotide Array Sequence Analysis
  • Oncogene Proteins v-abl / antagonists & inhibitors
  • Oncogene Proteins v-abl / genetics
  • Oncogene Proteins v-abl / metabolism*
  • Piperazines / pharmacology
  • Polyribosomes / drug effects
  • Polyribosomes / genetics
  • Precursor Cells, B-Lymphoid / drug effects
  • Precursor Cells, B-Lymphoid / metabolism
  • Precursor Cells, B-Lymphoid / pathology
  • Protein Biosynthesis* / drug effects
  • Pyrimidines / pharmacology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism
  • Transcriptome* / drug effects
  • Transcriptome* / genetics

Substances

  • Benzamides
  • Oncogene Proteins v-abl
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • Imatinib Mesylate
  • TOR Serine-Threonine Kinases
  • Sirolimus